FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Amarin's Trailing 12-Month Free Cash Flow is €22.2 Mil, and Market Cap is €297.8 Mil. Therefore, Amarin's FCF Yield % for today is 7.45%.
The historical rank and industry rank for Amarin's FCF Yield % or its related term are showing as below:
STU:EH3'
s FCF Yield % Range Over the Past 10 Years
Min: -47.59 Med: -3.51 Max: 8.76
Current: 7.45
During the past 13 years, the highest FCF Yield % of Amarin was 8.76%. The lowest was -47.59%. And the median was -3.51%.
STU:EH3's FCF Yield % is ranked better than 83.2% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.665
vs STU:EH3: 7.45
Amarin's FCF Margin % for the quarter that ended in Mar. 2026 was 14.16%.
Amarin FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Amarin FCF Yield % Related Terms
Amarin FCF Yield % Historical Data
* Premium members only.
The historical data trend for Amarin's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EH3 vs SCLX, MIRA, NSRX: FCF Yield % Comparison
For the Drug Manufacturers - General subindustry, Amarin's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amarin FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amarin's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Amarin's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin (STU:EH3) has a FCF Yield % of 7.45 as of Jul. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Amarin and its competitors. According to the industry distribution chart, Amarin ranks #169 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is Amarin's FCF Yield % too high?
Amarin's current FCF Yield % is 7.45. The Drug Manufacturers industry median FCF Yield % is 0.67. Amarin's value of 7.45 is 1020.3% above this industry median. Based on the distribution chart, Amarin ranks #169 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amarin has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Amarin's FCF Yield % compare to SCLX and MIRA?
According to the Drug Manufacturers industry distribution chart, Amarin ranks #169 out of 1006 companies for FCF Yield %. This places Amarin in the top 17% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Amarin's value of 7.45 is 1020.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amarin's current FCF Yield % of 7.45 is 1020.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Amarin and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amarin's current FCF Yield % is 7.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Amarin (STU:EH3) has a current FCF Yield % of 7.45. The stock's GF Value™ is €10.26, compared to a current price of €14.10 — trading 37.4% above its estimated fair value. The current FCF Yield % is 7.45 and 1020.3% above the Drug Manufacturers industry median of 0.67. Amarin's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Amarin (STU:EH3), the current FCF Yield % is 7.45 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amarin (STU:EH3) Overvalued in 2026?
Based on GuruFocus' analysis, Amarin stock appears to be overvalued.
The current stock price of €14.10 is trading 37.4% above its estimated GF Value™ of €10.26.
Key valuation signals for STU:EH3:
FCF Yield %: 7.45
GF Value™: €10.26 vs. price of €14.10 (37.4% above fair value)
Industry Position: 1020.3% above the Drug Manufacturers median (#169 of 1006)
No single metric tells the full story. See the STU:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
54GF Score
Get the complete analysis for STU:EH3
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EH3 has been successfully added to your 
